High-Dose Epirubicin in the Prophylactic Treatment of T1G2 Superficial Bladder Tumors

Torelli, F.; Catanzaro, F.; Conti, Giario; Comeri, C.G.; Risi, Oreste; Pino, Ramiro; Lissoni, G.; Borin, R.; Minocci, D.; Monesi, G.; Baresi, A.; Perego, Silvia; Caruso, G.; Scardino, G.

doi:10.1159/000052551

Cited by 6 publications

(1 citation statement)

References 13 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Intravesical epirubicin is a worthwhile therapeutical agent for superficial bladder cancer therapy [7]; a relationship between dose and toxicity of such a drug has also been demonstrated [3,4,8]. In this study the interesting therapeutical performances of such an agent have again been confirmed but the increase of side effects related to the increased epirubicin dosage was balanced by doubling the instillation interval.…”

Section: Discussionsupporting

confidence: 54%

Delayed High-Dose Intravesical Epirubicin Therapy of Superficial Bladder Cancer

Bassi

Longo²,

Saraeb³

et al. 2002

Urol Int

View full text Add to dashboard Cite

Introduction: Intravesical epirubicin is a widely used agent for the treatment of superficial bladder cancer. A direct relationship between dose and activity has been reported: unfortunately the dose increase also increased the frequency and the intensity of treatment-related side effects. Materials and Methods: A phase 2 trial was designed to evaluate the toxicity and the activity of a delayed (biweekly) high-dose (80 mg) epirubicin therapy of superficial bladder cancer. Thirty patients with intermediate risk superficial bladder cancer (stage mTa, G2) have been treated with transurethral resection and epirubicin intravesical therapy: the patients were given 80 mg epirubicin in 50 ml sterile saline every 2 weeks for 6 times (delayed regimen). The follow-up ranged from 3 to 26 months. Eleven of 30 (37%) patients experienced a local adverse reaction to intravesical epirubicin requiring specific medication (grade ≧2 according to NCI-CTC v.2.0, 1999). No systemic toxicity related to the treatment was observed. Results: Out of the 29 evaluable patients, 22 (76%) were free of disease after the induction course, 6 (21%) had superficial bladder cancer recurrences and 1 (3%) experienced tumor progression. Conclusion: A delayed (biweekly instillation) high-dose (80 mg) intravesical epirubicin regimen was acceptable in terms of side effects and showed a worthwhile therapeutical impact in patients with intermediate risk superficial bladder cancer.

show abstract

Section: Discussionsupporting

confidence: 54%